SG11201703064WA - Compositions and methods for treating insomnia - Google Patents

Compositions and methods for treating insomnia

Info

Publication number
SG11201703064WA
SG11201703064WA SG11201703064WA SG11201703064WA SG11201703064WA SG 11201703064W A SG11201703064W A SG 11201703064WA SG 11201703064W A SG11201703064W A SG 11201703064WA SG 11201703064W A SG11201703064W A SG 11201703064WA SG 11201703064W A SG11201703064W A SG 11201703064WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating insomnia
insomnia
treating
Prior art date
Application number
SG11201703064WA
Other languages
English (en)
Inventor
Margaret Moline
Gina PASTINO
Yurie AKIMOTO
Yasuhiro Zaima
Nobuya Suzuki
Nobuo Yoshida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201703064WA publication Critical patent/SG11201703064WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
SG11201703064WA 2014-10-23 2015-10-21 Compositions and methods for treating insomnia SG11201703064WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (fr) 2014-10-23 2015-10-21 Compositions et méthodes pour traiter l'insomnie

Publications (1)

Publication Number Publication Date
SG11201703064WA true SG11201703064WA (en) 2017-05-30

Family

ID=55761025

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007759RA SG10202007759RA (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia
SG11201703064WA SG11201703064WA (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202007759RA SG10202007759RA (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Country Status (14)

Country Link
US (3) US10188652B2 (fr)
EP (1) EP3209298B1 (fr)
JP (1) JP6659681B2 (fr)
KR (1) KR102444608B1 (fr)
CN (1) CN107810006B (fr)
AU (1) AU2015336463B2 (fr)
BR (1) BR112017007063A2 (fr)
CA (1) CA2964504C (fr)
ES (1) ES2843952T3 (fr)
IL (1) IL251759B (fr)
MX (1) MX2017004950A (fr)
RU (1) RU2703297C2 (fr)
SG (2) SG10202007759RA (fr)
WO (1) WO2016063995A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703297C2 (ru) 2014-10-23 2019-10-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Композиции и способы для лечения бессонницы
KR20230043227A (ko) 2016-05-12 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 일주기 리듬 수면 장애를 치료하는 방법
KR20230124110A (ko) 2016-08-10 2023-08-24 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
EP3883562A4 (fr) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. Formes purifiées de rofécoxib et procédés de fabrication et d'utilisation
WO2020263253A1 (fr) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant destiné au traitement des troubles du sommeil
CA3144067A1 (fr) * 2019-06-26 2020-12-30 Eisai R&D Management Co., Ltd. Lemborexant pour le traitement de problemes de sommeil
CA3154321A1 (fr) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 destine a etre utilise dans le traitement de la narcolepsie
BR112022002949A2 (pt) 2019-09-13 2022-06-07 Eisai R&D Man Co Ltd Composição farmacêutica para tratar insônia
AU2020408557A1 (en) 2019-12-20 2022-08-11 Eisai R&D Management Co., Ltd. Use of lemborexant for treating insomnia
IL294033A (en) 2020-01-16 2022-08-01 Eisai R&D Man Co Ltd Medicinal substance of lamborexant and medical preparation containing it
BR112022020924A2 (pt) 2020-04-19 2023-02-14 Idorsia Pharmaceuticals Ltd Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
WO2024064897A1 (fr) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Procédés de réduction de la neurodégénérescence associée à des maladies neurodégénératives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
WO1996034877A1 (fr) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Recepteur de neuropeptides humain
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
CA2581657A1 (fr) 2004-09-23 2006-03-30 Pfizer Products Inc. Agonistes du recepteur de thrombopoietine
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
EA015256B1 (ru) 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
WO2007129188A1 (fr) 2006-05-10 2007-11-15 Pfizer Japan Inc. Composé de cyclopropanecarboxamide
EP2064186A1 (fr) 2006-09-11 2009-06-03 Glaxo Group Limited Composés azabicycliques en tant qu'inhibiteurs de réabsorption de monoamines
ES2350460T3 (es) 2006-09-29 2011-01-24 Actelion Pharmaceuticals Ltd. Derivados de 3-aza-biciclo[3.1.0]hexano.
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
EP2203415B1 (fr) 2007-09-21 2016-10-26 Sanofi (cyclopropane-phényl)-phényl-oxalamide, son procédé de fabrication et son utilisation en tant que médicament
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
KR101823339B1 (ko) * 2010-02-15 2018-01-31 코닌클리케 필립스 엔.브이. 제어 채널 간섭의 완화
US8268848B2 (en) * 2010-09-22 2012-09-18 Eisai R&D Management Co., Ltd. Cyclopropane compound
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
RU2703297C2 (ru) 2014-10-23 2019-10-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Композиции и способы для лечения бессонницы

Also Published As

Publication number Publication date
WO2016063995A1 (fr) 2016-04-28
AU2015336463B2 (en) 2020-06-18
SG10202007759RA (en) 2020-09-29
RU2017112308A (ru) 2018-11-26
MX2017004950A (es) 2018-01-16
RU2703297C2 (ru) 2019-10-16
US20190201399A1 (en) 2019-07-04
IL251759B (en) 2021-01-31
CN107810006A (zh) 2018-03-16
CN107810006B (zh) 2021-03-30
IL251759A0 (en) 2017-06-29
JP6659681B2 (ja) 2020-03-04
CA2964504A1 (fr) 2016-04-28
EP3209298A1 (fr) 2017-08-30
US10188652B2 (en) 2019-01-29
CA2964504C (fr) 2022-08-23
KR102444608B1 (ko) 2022-09-20
BR112017007063A2 (pt) 2018-02-14
US11026944B2 (en) 2021-06-08
KR20170068478A (ko) 2017-06-19
US20170252342A1 (en) 2017-09-07
US10702529B2 (en) 2020-07-07
US20200268754A1 (en) 2020-08-27
EP3209298A4 (fr) 2018-06-20
ES2843952T3 (es) 2021-07-21
RU2017112308A3 (fr) 2019-05-08
AU2015336463A1 (en) 2017-05-04
EP3209298B1 (fr) 2020-12-02
JP2017531683A (ja) 2017-10-26

Similar Documents

Publication Publication Date Title
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
IL251759B (en) Preparations and methods for treating insomnia
GB2535253B (en) Compositions and methods
SG11201700079VA (en) Combination therapy compositions and methods for treating cancers
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
RS61929B1 (sr) Postupci i sastavi za tretman raka
IL246879B (en) Preparations of Epilimod and methods of using them
RS61703B1 (sr) Kompozicije i postupci za lečenje i prevenciju zapaljenja
IL254963A0 (en) Preparations and methods for the treatment of autism
IL251108A0 (en) Preparations and methods for the treatment of acute radiation syndrome
ZA201605109B (en) Compositions and methods for treating neutropenia
HK1246206A1 (zh) 用於治療青光眼的組合物和方法
EP3262065C0 (fr) Procédés et compositions de traitement des dystroglycanopathies
PL3220908T3 (pl) Kompozycje i sposoby leczenia endometriozy
ZA201703771B (en) Compositions and methods for treating hyperkalemia
GB201502983D0 (en) Composition and process
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
PT3096779T (pt) Composições e métodos para tratamento de hemorragia intracerebral
IL257407A (en) Compositions and methods for treating wounds
GB201402915D0 (en) Compositions and methods
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201407949D0 (en) Compositions and methods for treating biofilms
GB201421947D0 (en) Elecroplating method and composition
GB201419559D0 (en) Therapeutic compositions and methods
GB201403212D0 (en) Compositions and methods